BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 20972333)

  • 1. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
    Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
    J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1: a weak spot in KRAS-induced transformation.
    Licciulli S; Kissil JL
    J Clin Invest; 2010 Nov; 120(11):3804-7. PubMed ID: 20972324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
    Wu C; Wang S; Xu C; Tyler A; Li X; Andersson C; Oji Y; Sugiyama H; Chen Y; Li A
    Cell Physiol Biochem; 2015; 35(2):647-62. PubMed ID: 25613309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
    Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
    Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
    Vandal G; Geiling B; Dankort D
    PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
    Okudela K; Yazawa T; Woo T; Sakaeda M; Ishii J; Mitsui H; Shimoyamada H; Sato H; Tajiri M; Ogawa N; Masuda M; Takahashi T; Sugimura H; Kitamura H
    Am J Pathol; 2009 Aug; 175(2):867-81. PubMed ID: 19608870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
    Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
    Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.
    Tran PT; Shroff EH; Burns TF; Thiyagarajan S; Das ST; Zabuawala T; Chen J; Cho YJ; Luong R; Tamayo P; Salih T; Aziz K; Adam SJ; Vicent S; Nielsen CH; Withofs N; Sweet-Cordero A; Gambhir SS; Rudin CM; Felsher DW
    PLoS Genet; 2012; 8(5):e1002650. PubMed ID: 22654667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
    Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
    Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetics and biology of KRAS in lung cancer.
    Westcott PM; To MD
    Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
    Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
    McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
    Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
    Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
    Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
    Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
    Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
    Vallejo A; Perurena N; Guruceaga E; Mazur PK; Martinez-Canarias S; Zandueta C; Valencia K; Arricibita A; Gwinn D; Sayles LC; Chuang CH; Guembe L; Bailey P; Chang DK; Biankin A; Ponz-Sarvise M; Andersen JB; Khatri P; Bozec A; Sweet-Cordero EA; Sage J; Lecanda F; Vicent S
    Nat Commun; 2017 Feb; 8():14294. PubMed ID: 28220783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and YAP1 converge to regulate EMT and tumor survival.
    Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
    Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.